v3.26.1
REVENUES
12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
REVENUES

NOTE 17 – REVENUES

 

Disaggregation of Revenue

 

The following table disaggregates the Company’s revenues by major revenue streams.

 

Revenue stream:          
   Years Ended December 31, 
   2024   2023 
   (in thousands) 
Revenue stream:          
Cell process development services and hospital services  $1,020   $515 
License fees   15    15 
Total  $1,035   $530 

 

A breakdown of the revenues per customer what constituted at least 10% of revenues is as follows:

 

   2024   2023 
   Years Ended December 31, 
   2024   2023 
   (in thousands) 
Revenue earned:          
Customer A (United States)   492    - 
Customer B (United States)   300    280 
Customer C (United States)   -    90 
Customer D (United States)   150    280 

 

 

Contract Assets and Liabilities

 

Contract assets are mainly comprised of accounts receivable net of allowance for doubtful debts, which includes amounts billed and currently due from customers.

 

The activity for accounts receivable is comprised of:

 

   2024   2023 
   Years Ended December 31, 
   2024   2023 
   (in thousands) 
         
Balance as of beginning of period  $88   $36,183 
Deconsolidation of Octomera   82    (5,985)
Additions   670    560 
Collections   (1,268)   (6,230)
Allowances for credit losses   469    (24,388)
Exchange rate differences   (1)   (52)
Balance as of end of period  $40   $88 

 

The activity for contract liabilities is comprised of:

 

   2024   2023 
   Years Ended December 31, 
   2024   2023 
   (in thousands) 
         
Balance as of beginning of period  $200   $70 
Reconsolidation (deconsolidation) of Octomera   110    (106)
Deconsolidation of OBI   (60)   - 
Additions   300    236 
Realizations   (445)   - 
Balance as of end of period  $105   $200